grinboss

Alnylam Pharmaceuticals

ALNY

What is it worth to you? Move six assumptions and see what value per share you get, and where you stand against the price and other users.

Value Alnylam Pharmaceuticals (ALNY) with your own assumptions and see where you stand against the price and other users.

Its accounts, year by year

Year endSalesGrowthMargin
12/201647—−740.2%
12/20179090.7%−453.0%
12/201875−16.7%−877.0%
12/2019220193.4%−347.9%
12/2020493124.3%−139.7%
12/202184471.3%−64.3%
12/20221,03722.9%−53.4%
12/20231,82876.2%−3.3%
12/20242,24823.0%4.2%
12/20253,71465.2%22.9%

Sales in millions of dollars. The margin is the operating margin before stock pay, as a percentage of sales. Each row is a fiscal year, by the month it ends. Source: the reports Alnylam Pharmaceuticals files with the SEC, the US securities regulator; the latest is for the fiscal year ended December 31, 2025. See the report.

The model's starting point

  • Sales growth, years 1 to 10: 40.0% a year.
  • Sales growth after year 10: 2.5% a year.
  • Operating margin, before stock pay: 4.2% of sales.
  • Working capital needed to grow: −$28.0 per $100 of new sales.
  • Capital spending: 3.4% of sales.
  • Stock pay to employees: 23.3% of sales.
  • Discount rate, the same for every company: 10%.

These are the six assumptions the page starts with; each user moves them as they see fit.

Reference points

They come from its accounts and its share price, compared with the median of the companies on grinboss. They are not a recommendation.

For

  • Its margin has risen over these years, from −740% to 4%.
  • Its sales grew 62.4% a year on average over 9 years, from $0.0 billion to $3.7 billion; the median of grinboss companies is 6.6%.
  • It has more cash than debt.
  • Growing brings it cash: it collects from its customers before it pays its suppliers.

Against

  • Its margin jumps from one year to the next: 179.0 points on average, and up to 529.1 in a single year; the median is 2.8 points.
  • It generated free cash flow in only 0 of the last 5 years.
  • Its stock pay to employees is high: 23.3% of sales, more than the median (1.5%). That is a part of the company that stops belonging to the shareholders.
  • It is one of the smallest in grinboss: it sells $3.7 billion a year; the median is $15.1 billion.

Next results: January 11, 2027.

Other companies in its sector (Health Care)

Amgen (AMGN) · Baxter International (BAX) · Becton Dickinson (BDX) · Biogen (BIIB) · Bristol Myers Squibb (BMY) · Boston Scientific (BSX) · Cardinal Health (CAH) · Cooper Companies (COO) · All companies

Loading the model…